<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6882492</article-id><article-id pub-id-type="pmid">31752563</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1693555</article-id><article-id pub-id-type="publisher-id">1693555</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Rapid Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors</article-title><alt-title alt-title-type="left-running-head">D. J. Hong et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Dong Jin</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>Seung Hyun</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jisook</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>Danbee</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Young Gil</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Suh</surname><given-names>Kwee Hyun</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Min</surname><given-names>Kyung Hoon</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>College of Pharmacy, Chung-Ang University</institution>, <city>Seoul</city>, <country>Republic of Korea</country></aff><aff id="AF0002"><label>b</label><institution>Hanmi Research Center, Hanmi Pharm. Co., Ltd</institution>., <city>Gyeonggi-Do</city>, <country>Republic of Korea</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Kyung Hoon Min <email>khmin@cau.ac.kr</email><institution>College of Pharmacy, Chung-Ang University</institution>, <city>Seoul</city>, <country>Republic of Korea</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>11</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><volume>35</volume><issue>1</issue><fpage seq="22">227</fpage><lpage>234</lpage><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_35_1693555.pdf"/><abstract><title>Abstract</title><p>A novel series of thieno[3,2-<italic>d</italic>]pyrimidine derivatives were synthesised and their inhibitory effects against diacylglycerol acyltransferase 1 (DGAT-1) were assessed. cis-Isomer <bold>17a</bold> showed potent and selective inhibitory activity against DGAT-1 in SF9 cells. In addition, <bold>17a</bold> had an acceptable pharmacokinetic profile and accumulated mainly in the small intestine and liver. Oral administration of <bold>17a</bold> led to a significant reduction in plasma triacylglycerol level during an oral lipid tolerance test (OLTT) in murine and canine models. Taken together, <bold>17a</bold> is a high-quality candidate that deserves further investigation.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>DGAT-1</kwd><kwd>obesity</kwd><kwd>small molecules</kwd><kwd>thienopyrimidine</kwd><kwd>type 2 diabetes</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Advanced Research Centre Programme</institution></institution-wrap></funding-source><award-id>2015R1A5</award-id><award-id>A1008958</award-id></award-group><funding-statement>This research was supported by the Advanced Research Centre Programme (2015R1A5 A1008958) funded by the Korean Government.</funding-statement></funding-group></support-group><counts><fig-count count="5"/><table-count count="5"/><page-count count="8"/><word-count count="4626"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001" disp-level="1"><title>Introduction</title><p>Obesity is characterised by abnormal fat accumulation due to a systemic dysfunction of energy homeostasis. It is a significant risk factor for diabetes, hypertension, cardiovascular disease, and non-alcoholic fatty liver disease<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. Excessive accumulation of triglycerides (or triacylglycerol, TAG) in adipocytes and non-adipocytes, including in the liver, skeletal muscle, myocardium, and pancreas, is a crucial feature of obesity<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. In particular, abnormal TAG levels increases the risk of metabolic syndrome, characterised by as insulin resistance, dyslipidemia and cardiomyopathy<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>.</p><p>Therefore, preventing excessive accumulation of TAG could be beneficial in the treatment of metabolic diseases such as obesity and type 2 diabetes. Two routes of TAG biosynthesis have been identified: the glycerol phosphate pathway, and the monoacylglycerol pathway<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>. Both routes have a common intermediate, diacylglycerol (DAG), which is then converted to TAG by acyl CoA: diacylglycerol acyltransferase (DGAT)<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>. DGAT exists as two isoforms, DGAT-1 and DGAT-2, which share minimal sequence homology<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>. These enzymes catalyse the final dedicated step in TAG synthesis: i.e. the esterification of a fatty acid moiety to DAG to generate TAG. DGAT-1 is highly expressed in the small intestine, adipose tissue, and liver<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>. DGAT-1 deficient mice showed a significant reduction in the postprandial increase of plasma TAG and were resistant to diet-induced obesity due to increased energy expenditure. Moreover, the <italic>DGAT1</italic> knockout mice had enhanced sensitivity to insulin and leptin. Indeed, DGAT-1 inhibitors had significant pharmacologic effects, including decreased TAG, which were consistent with the <italic>DGAT1</italic> knockout mice phenotypes<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>. However, <italic>DGAT2</italic> knockout mice had extremely low levels of TAG, and their skin could not protect against moisture, so these mice died after birth<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>. Therefore, selective DGAT-1 inhibitors have been developed to manage metabolic diseases such as obesity and type 2 diabetes<xref rid="CIT0009" ref-type="bibr"><sup>9&#x02013;11</sup></xref>. Pharmaceutical companies, including AstraZeneca (<bold>1</bold>)<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>, Novartis (<bold>2</bold>)<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>, Pfizer (<bold>3</bold>)<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>, and Abbott (<bold>4</bold>)<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>, and Hoffmann-La Roche (<bold>5</bold>)<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref> are developing selective DGAT-1 inhibitors, whose structures are described in <xref ref-type="fig" rid="F0001">Figure 1</xref>. Other novel DGAT1 inhibitors have also been reported<xref rid="CIT0017" ref-type="bibr"><sup>17&#x02013;19</sup></xref>.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>(a) Structures of reported DGAT1 inhibitors; (b) diagram showing structural features of DGAT-1 inhibitors.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1693555_F0001_B"/></fig><p>Herein, we described the discovery of novel thieno[3,2-<italic>d</italic>]pyrimidine derivatives as DGAT-1 inhibitors. Target molecules were designed based on a bioisosteric replacement strategy (<xref ref-type="fig" rid="F0002">Figure 2</xref>). Introduction of a heterobicylcle instead of a phenyl linker was attempted. Thienopyrimidines showed various pharmacologic activities as a privileged scaffold<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>, and the introduction of thieno[3,2-<italic>d</italic>]pyrimidine was the first approach to designing novel inhibitors based on the structural features of reported DGAT-1 inhibitors.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>A schematic strategy for the design of target molecules.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1693555_F0002_C"/></fig></sec><sec sec-type="materials" id="S0002" disp-level="1"><title>Materials and methods</title><sec id="S0002-S2001" disp-level="2"><title>Chemistry</title><p>All commercial chemicals and solvents were reagent grade and were used without further purification. Completion of the reactions was monitored by analytical thin layer chromatography (TLC) using precoated glass-backed plates (E-Merck, silica gel 60 F<sub>254</sub> 0.25&#x02009;mm). For normal pressure and flash column chromatography purifications, Merck silica gel 60 (size 70&#x02013;230 and 230&#x02013;400 mesh, respectively) was used. <sup>1</sup>H and 13C NMR spectra were recorded with an Avance DPX-300 NMR spectrometer (Bruker, Germany) and Jeol 600&#x02009;MHz spectrometer (Jeol Resonance ECZ 600&#x02009;R, USA). All the <sup>1</sup>H and <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C NMR spectra were recorded in deuterated chloroform (CDCl<sub>3</sub>) with tetramethylsilane (TMS) as an internal standard or deuterated dimethyl sulfoxide (DMSO)-<italic>d6</italic> as solvents; chemical shifts are reported in <italic>&#x003b4;</italic> values (ppm) relative to the residual solvent peak. Multiplicity was indicated as follows: s (singlet); d (doublet); t (triplet); m (multiplet); dd (doublet of doublet); brs (broad singlet). Mass spectra were obtained on Waters Aquity UPLC/QTOF (Waters Corporation, USA). HPLC was used Agilent, 1200 series using capcellpak MGII (4.6&#x02009;&#x000d7;&#x02009;150&#x02009;mm, 5&#x02009;&#x003bc;m) eluted with a 30&#x02009;min gradient from 20&#x02013;70% acetonitrile in water.</p></sec><sec id="S0002-S2002" disp-level="2"><title>Synthesis of 17a and 17b</title><sec id="S0002-S2002-S3001" disp-level="3"><title><italic>Tert</italic>-butyl (4&#x02013;(7-bromothieno[3,2-d]pyrimidin-4-yl)phenyl)carbamate (8)</title><p>A mixture of 7-bromo-4-chlorothieno[3,2-<italic>d</italic>]pyrimidine <bold>6</bold> (13&#x02009;g, 52.10&#x02009;mmol, CY C37043, KindChem Corporation, China), <italic>t</italic>-butyl 4&#x02013;(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenylcarbamate <bold>7</bold> (20&#x02009;g, 62.70&#x02009;mmol<bold>)</bold>, tetrakis(triphenylphosphine)palladium (3.16&#x02009;g, 2.73&#x02009;mmol) and sodium carbonate (8.28&#x02009;g. 78.12&#x02009;mmol) were added to 100&#x02009;mL of 1,4-dioxane/water (4:1), and then stirred at 80&#x02009;&#x000b0;C for 18&#x02009;h under argon atmosphere. The organic layer was extracted with 300&#x02009;mL of ethyl acetate and 300&#x02009;mL of water, dried over anhydrous magnesium sulphate, and then concentrated <italic>in vacuo</italic>. Subsequently, 30&#x02009;mL of methanol was added, and the resulting mixture was stirred to precipitate out solids, and then filtered to obtain 12.5&#x02009;g of the yellow title compound.</p><p><sup>1</sup>H-NMR (300&#x02009;MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic> 9.80(s, 1H), 8.18(d, <italic>J</italic>&#x02009;=&#x02009;6.9&#x02009;Hz, 2H), 8.04(s, 1H), 7.62(d, <italic>J</italic>&#x02009;=&#x02009;6.9&#x02009;Hz, 2H), 6.76(s, 1H), 1.58(s, 9H).</p></sec><sec id="S0002-S2002-S3002" disp-level="3"><title>Methyl 2&#x02013;(4&#x02013;(4-(4-((<italic>tert</italic>-butoxycarbonyl)amino)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohex-3-en-1-yl)acetate (10)</title><p>A mixture of <bold>8 (</bold>0.56&#x02009;g, 1.38&#x02009;mmol), 2&#x02013;(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)acetate <bold>9</bold> (0.5&#x02009;g, 1.78&#x02009;mmol), which was prepared according to the reported method<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>, and tetrakis(triphenylphosphine)palladium (94.9&#x02009;mg, 0.08&#x02009;mmol) was added to a solution of 2.06&#x02009;mL of 2&#x02009;<italic>N</italic> aqueous sodium carbonate and 8.2&#x02009;mL of 1,4-dioxane, and then stirred at 100&#x02009;&#x000b0;C for 12&#x02009;h under argon. The reaction mixture was extracted with 300&#x02009;mL of ethyl acetate and 300&#x02009;mL of water. The organic layer was dried with anhydrous magnesium sulphate, filtered and then concentrated. Subsequently, methanol was added to the resulting solution, stirred to precipitate out solids, and then filtered to obtain 315&#x02009;mg of the yellow title compound.</p><p><sup>1</sup>H-NMR (300&#x02009;MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic> 9.30(s, 1H), 8.17(d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 2H), 7.43(s, 1H), 7.59(d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 2H), 7.16(bs, 1H), 6.69(s, 1H), 3.71(s, 3H), 2.64&#x02009;&#x0223c;&#x02009;2.38(m, 3H), 2.2 6&#x02009;&#x0223c;&#x02009;2.02(m, 6H), 1.56(s, 9H). LCMS (ESI) m/z 480.2 [M&#x02009;+&#x02009;H]<sup>+</sup>; HRMS calcd for C<sub>26</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub>S [M&#x02009;+&#x02009;H]<sup>+</sup> 480.1957, found 480.1986</p></sec><sec id="S0002-S2002-S3003" disp-level="3"><title>Methyl 2&#x02013;(4&#x02013;(4-(4-((t-butoxycarbonyl)amino)phenyl)thieno[3,2-<italic>d</italic>]pyrimidin-7-yl)cyclohexyl) acetate (11)</title><p>To a solution of <bold>10</bold> (315&#x02009;mg, 0.66&#x02009;mmol) in ethanol (50&#x02009;mL) and 1,4-dioxane (20&#x02009;mL) was added 20% charcoal-shaped palladium hydroxide (158&#x02009;mg, 50%w/w). The mixture was stirred at room temperature under H<sub>2</sub> overnight. The reaction mixture was filtered through Celite, and then the filtrate was concentrated to obtain the title compound <bold>11</bold> (190&#x02009;mg), which was used in the following step without further purification.</p><p><sup>1</sup>H-NMR (300&#x02009;MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic> 9.26(s, 2H), 8.17(d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, 4H), 7.69(s, 1H), 7.63(s, 1H), 7.62(d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 4H), 6.71(s, 2H), 3.69(s, 6H), 3.3 2&#x02009;&#x0223c;&#x02009;3.17(m, 2H), 2.50(d, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, 2H), 2.4 3&#x02009;&#x0223c;&#x02009;2.35(m, 1H), 2.33(d, <italic>J</italic>&#x02009;=&#x02009;6.6&#x02009;Hz, 2H), 2.2 8&#x02009;&#x0223c;&#x02009;2.18(m, 2H), 2.0 7&#x02009;&#x0223c;&#x02009;1.19(m, 9H), 1.7 3&#x02009;&#x0223c;&#x02009;1.60(m, 4H), 1.57(s, 18H), 1.4 0&#x02009;&#x0223c;&#x02009;1.25(m, 2H). LCMS (ESI) m/z 482.2 [M&#x02009;+&#x02009;H]<sup>+</sup>; HRMS calcd for C<sub>26</sub>H<sub>31</sub>N<sub>3</sub>O<sub>4</sub>S [M&#x02009;+&#x02009;H]<sup>+</sup> 482.2114, found 482.2258</p></sec><sec id="S0002-S2002-S3004" disp-level="3"><title>Methyl 2&#x02013;(4&#x02013;(4-(4-aminophenyl)thieno[3,2-<italic>d</italic>]pyrimidin-7-yl)cyclohexyl)acetate (12)</title><p>To a solution of <bold>11</bold> (280&#x02009;mg, 0.58&#x02009;mmol) in dichloromethane (5&#x02009;mL) was added 0.6&#x02009;mL of trifluoroacetic acid. The mixture was stirred at room temperature for 12&#x02009;h. Then the reaction mixture was concentrated to a residue that was partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The organic layer was separated from the aqueous layer, washed with brine, dried over anhydrous magnesium sulphate, and then concentrated to afford 190&#x02009;mg of the title compound.</p><p><sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-<italic>d<sub>6</sub></italic>): <italic>&#x003b4;</italic> 9.08(s, 2H), 8.13(s, 1H), 8.04(s, 1H), 8.01(d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, 4H), 6.76(d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, 4H), 5.90(s, 4H), 3.60(s, 6H), 3.3 0&#x02009;&#x0223c;&#x02009;3.10(m, 2H), 2.48(d, 2H), 2.28(d, <italic>J</italic>&#x02009;=&#x02009;6.5&#x02009;Hz, 2H), 2.2 5&#x02009;&#x0223c;&#x02009;2.13(m, 1H), 2.2 8&#x02009;&#x0223c;&#x02009;2.16(m, 3H), 2.1 0&#x02009;&#x0223c;&#x02009;1.98(m, 2H), 1.9 0&#x02009;&#x0223c;&#x02009;1.46(m, 14H), 1.3 0&#x02009;&#x0223c;&#x02009;1.10(m, 2H).</p></sec><sec id="S0002-S2002-S3005" disp-level="3"><title>Methyl 2&#x02013;(4&#x02013;(4-(4-(3&#x02013;(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate (13)</title><p>To a solution of <bold>12</bold> (3.1&#x02009;g, 8.13&#x02009;mmol) in anhydrous tetrahydrofuran (60&#x02009;mL) was added 3-chlorophenyl isocyanate (1.37&#x02009;g, 8.92&#x02009;mmol). The mixture was stirred at room temperature for 18&#x02009;h. The mixture was concentrated in part and diluted with diethyl ether to give a precipitate, which was filtered to afford 4.06&#x02009;g of a light-yellow title compound.</p><p><sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-<italic>d<sub>6</sub></italic>): <italic>&#x003b4;</italic> 9.21(s, 2H), 9.16(s, 2H), 9.03(s, 2H), 8.24(s, 1H), 8.2 1&#x02009;&#x0223c;&#x02009;8.15(m, 5H), 7.7 4&#x02009;&#x0223c;&#x02009;7.71(m, 6H), 7.4 0&#x02009;&#x0223c;&#x02009;7.29(m, 4H), 7.1 0&#x02009;&#x0223c;&#x02009;7.00(m, 2H), 3.61(s, 6H), 3.3 2&#x02009;&#x0223c;&#x02009;3.04(m, 2H), 2.46(d, 2H), 2.29(d, <italic>J</italic>&#x02009;=&#x02009;6.5&#x02009;Hz, 2H), 2.2 2&#x02009;&#x0223c;&#x02009;2.14(m, 1H), 2.2 1&#x02009;&#x0223c;&#x02009;2.01(m, 2H), 1.8 9&#x02009;&#x0223c;&#x02009;1.49(m, 14H), 1.3 0&#x02009;&#x0223c;&#x02009;1.11(m, 2H). LCMS (ESI) m/z 535.2 [M&#x02009;+&#x02009;H]<sup>+</sup>; HRMS calcd for C<sub>28</sub>H<sub>27</sub>ClN<sub>4</sub>O<sub>3</sub>S [M&#x02009;+&#x02009;H]<sup>+</sup> 535.1571, found 535.1793</p></sec><sec id="S0002-S2002-S3006" disp-level="3"><title>Methyl <italic>cis</italic>-2&#x02013;(4&#x02013;(4-(4-(3&#x02013;(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate (15a)</title><p><bold>13</bold> (150&#x02009;mg, 0.28&#x02009;mmol) was added to ethyl acetate (2&#x02009;mL) and stirred at 70&#x02009;&#x000b0;C for 12&#x02009;h, and then cooled to room temperature to give a solid. The solid (<bold>15b</bold>, 72&#x02009;mg) was filtered, and then the filtrate was concentrated and the residue was purified by silica gel column chromatography to give 76&#x02009;mg of the yellow title compound <bold>15a</bold>.</p><p><sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-<italic>d<sub>6</sub></italic>): <italic>&#x003b4;</italic> 9.23(s, 1H), 9.17(s, 1H), 9.04(s, 1H), 8.25(s, 1H), 8.19(d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 2H), 7.7 5&#x02009;&#x0223c;&#x02009;7.72(m, 3H), 7.3 3&#x02009;&#x0223c;&#x02009;7.31(m, 2H), 7.0 7&#x02009;&#x0223c;&#x02009;7.03(m, 1H), 3.61(s, 3H), 3.3 1&#x02009;&#x0223c;&#x02009;3.18(m, 1H), 2.52(d, 2H), 2.2 8&#x02009;&#x0223c;&#x02009;2.14(m, 1H), 1.8 9&#x02009;&#x0223c;&#x02009;1.49(m, 8H). LCMS (ESI) m/z 535.2 [M&#x02009;+&#x02009;H]<sup>+</sup>; HRMS calcd for C<sub>28</sub>H<sub>27</sub>ClN<sub>4</sub>O<sub>3</sub>S [M&#x02009;+&#x02009;H]<sup>+</sup> 535.1571, found 535.1793</p></sec><sec id="S0002-S2002-S3007" disp-level="3"><title>Methyl <italic>trans</italic>-2&#x02013;(4&#x02013;(4-(4-(3&#x02013;(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate (15b)</title><p><sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 9.23(s, 1H), 9.23(s, 1H), 9.16(s, 1H), 9.03(s, 1H), 8.19(d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 2H), 8.16(s, 1H), 7.7 5&#x02009;&#x0223c;&#x02009;7.72(m, 3H), 7.3 6&#x02009;&#x0223c;&#x02009;7.29(m, 2H), 7.0 7&#x02009;&#x0223c;&#x02009;7.03(m, 1H), 3.61(s, 3H), 3.11(t, <italic>J</italic>&#x02009;=&#x02009;11.9&#x02009;Hz, 1H), 2.30(d, <italic>J</italic>&#x02009;=&#x02009;6.5&#x02009;Hz, 2H), 2.1 3&#x02009;&#x0223c;&#x02009;2.01(m, 2H), 1.9 0&#x02009;&#x0223c;&#x02009;1.72(m, 3H), 1.6 8&#x02009;&#x0223c;&#x02009;1.50(m, 2H), 1.2 9&#x02009;&#x0223c;&#x02009;1.11(m, 2H). LCMS (ESI) m/z 535.2 [M&#x02009;+&#x02009;H]<sup>+</sup>; HRMS calcd for C<sub>28</sub>H<sub>27</sub>ClN<sub>4</sub>O<sub>3</sub>S [M&#x02009;+&#x02009;H]<sup>+</sup> 535.1571, found 535.1793</p></sec><sec id="S0002-S2002-S3008" disp-level="3"><title><italic>cis</italic>-2&#x02013;(4&#x02013;(4-(4-(3&#x02013;(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetic acid (16a)</title><p>To a solution of <bold>15a</bold> (7.8&#x02009;g, 14.58&#x02009;mmol) in tetrahydrofuran/methanol/water (120&#x02009;mL, 1:1:1) was added 1.17&#x02009;g of sodium hydroxide (29.25&#x02009;mmol), and the mixture was stirred. The reaction mixture was acidified with 1&#x02009;<italic>N</italic> HCl (pH was adjusted to between 5 and 6) to give a solid. The solid was filtered, and washed with water to afford <bold>16a</bold> quantitatively.</p><p><sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-<italic>d<sub>6</sub></italic>): <italic>&#x003b4;</italic> 9.28(s, 1H), 9.23(s, 1H), 9.16(s, 1H), 8.24(s, 1H), 8.19(d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 2H), 7.7 5&#x02009;&#x0223c;&#x02009;7.72(m, 3H), 7.3 3&#x02009;&#x0223c;&#x02009;7.31(m, 2H), 7.1 0&#x02009;&#x0223c;&#x02009;7.00(m, 1H), 3.3 2&#x02009;&#x0223c;&#x02009;3.20(m, 1H), 2.39(d, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, 2H), 2.2 8&#x02009;&#x0223c;&#x02009;2.14(m, 1H), 1.9 0&#x02009;&#x0223c;&#x02009;1.50(m, 8H). <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C -NMR (150&#x02009;MHz, DMSO-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 174.08, 160.01, 158.32, 154.04, 152.20, 142.37, 142.10, 141.00, 133.20, 131.36, 130.43, 129.97, 129.20, 127.20, 121.70, 118.21, 117.66, 116.75, 37.03, 35.51, 30.03, 29.31, 27.18. LCMS (ESI) m/z 521.1 [M&#x02009;+&#x02009;H]<sup>+</sup>; HRMS calcd for C<sub>27</sub>H<sub>25</sub>ClN<sub>4</sub>O<sub>3</sub>S [M&#x02009;+&#x02009;H]<sup>+</sup> 521.1414, found 521.1441</p></sec><sec id="S0002-S2002-S3009" disp-level="3"><title><italic>trans</italic>-2&#x02013;(4&#x02013;(4-(4-(3&#x02013;(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetic acid (16b)</title><sec id="S0002-S2002-S3009-S4001" disp-level="4"><title>16b was obtained from the procedure described for 16a</title><p><sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 12.04(s, 1H), 9.29(s, 1H), 9.23(s, 1H), 9.16(s, 1H), 8.18(d, <italic>J</italic>&#x02009;=&#x02009;9.0&#x02009;Hz, 2H), 8.15(s, 1H), 7.7 5&#x02009;&#x0223c;&#x02009;7.72(m, 3H), 7.3 6&#x02009;&#x0223c;&#x02009;7.29(m, 2H), 7.0 7&#x02009;&#x0223c;&#x02009;7.02(m, 1H), 3.11(t, <italic>J</italic>&#x02009;=&#x02009;12.1, 1H), 2.19(d, <italic>J</italic>&#x02009;=&#x02009;6.7&#x02009;Hz, 2H), 2.1 3&#x02009;&#x0223c;&#x02009;2.01(m, 2H), 1.9 0&#x02009;&#x0223c;&#x02009;1.72(m, 3H), 1.6 8&#x02009;&#x0223c;&#x02009;1.50(m, 2H), 1.2 9&#x02009;&#x0223c;&#x02009;1.11(m, 2H). <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C -NMR (150&#x02009;MHz, DMSO-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 173.90, 159.93, 158.35, 154.10, 152.22, 142.36, 141.05, 133.19, 130.81, 130.41, 129.97, 129.17, 127.27, 121.68, 118.25, 117.70, 116.79, 41.60, 36.15, 34.13, 32.42, 32.05. LCMS (ESI) m/z 521.1 [M&#x02009;+&#x02009;H]<sup>+</sup>; HRMS calcd for C<sub>27</sub>H<sub>25</sub>ClN<sub>4</sub>O<sub>3</sub>S [M&#x02009;+&#x02009;H]<sup>+</sup> 521.1414, found 521.1441</p></sec></sec><sec id="S0002-S2002-S3010" disp-level="3"><title>Sodium <italic>cis</italic>-2&#x02013;(4&#x02013;(4-(4-(3&#x02013;(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate (17a)</title><p>To a solution of <bold>16a</bold> (7.6&#x02009;g, 14.59&#x02009;mmol) in 100&#x02009;mL of methanol was added 14&#x02009;mL of a 1&#x02009;<italic>N</italic> sodium hydroxide. The resulting mixture was stirred at room temperature for 2&#x02009;h. The solvent was removed to give 8.3&#x02009;g of the yellow title compound <bold>17a.</bold></p><p><sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 12.50(s, 1H), 12.37(s, 1H), 9.21(s, 1H), 8.23(s, 1H), 8.17(d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 2H), 7.7 5&#x02009;&#x0223c;&#x02009;7.72(m, 3H), 7.56 (d, <italic>J</italic>&#x02009;=&#x02009;9.0&#x02009;Hz, 1H), 7.27 (t, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, 1H), 6.96 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 3.3 2&#x02009;&#x0223c;&#x02009;3.18(m, 1H), 2.4 0&#x02009;&#x0223c;&#x02009;2.20(m, 3H), 2.0 0&#x02009;&#x0223c;&#x02009;1.60(m, 8H). <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C -NMR (150&#x02009;MHz, DMSO-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 178.28, 160.00, 158.50, 154.04, 153.53, 144.38, 142.88, 142.70, 132.90, 130.91, 130.04, 128.93, 128.77, 126.97, 120.44, 117.95, 117.40, 116.55, 41.40, 39.08, 30.92, 30.03, 27.70. LCMS (ESI) m/z 521.1 [M&#x02009;+&#x02009;H]<sup>+</sup>; HRMS calcd for C<sub>27</sub>H<sub>25</sub>ClN<sub>4</sub>O<sub>3</sub>S [M&#x02009;+&#x02009;H]<sup>+</sup> 521.1414, found 521.1441 (as free base)</p></sec><sec id="S0002-S2002-S3011" disp-level="3"><title>Sodium <italic>trans</italic>-2&#x02013;(4&#x02013;(4-(4-(3&#x02013;(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate (17b)</title><p><sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 12.27(s, 1H), 12.25(s, 1H), 9.18(s, 1H), 8.17(d, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz, 2H), 7.99(s, 1H), 7.89(d, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz, 2H), 7.83(s, 1H), 7.56(d, <italic>J</italic>&#x02009;=&#x02009;9.3&#x02009;Hz, 1H), 7.27(t, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, 1H), 6.96(d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H), 3.11(t, <italic>J</italic>&#x02009;=&#x02009;11.6, 1H), 2.1 0&#x02009;&#x0223c;&#x02009;1.83(m, 2H), 1.6 8&#x02009;&#x0223c;&#x02009;1.46(m, 2H), 1.2 9&#x02009;&#x0223c;&#x02009;1.11(m, 2H). <xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>C -NMR (150&#x02009;MHz, DMSO-<italic>d</italic><sub>6</sub>): <italic>&#x003b4;</italic> 178.21, 159.84, 158.38, 154.07, 153.42, 144.40, 142.93, 142.83, 132.90, 130.28, 130.05, 128.94, 128.60, 126.87, 120.48, 117.80, 117.32, 116.49, 46.16, 36.07, 35.92, 33.08, 32.68. LCMS (ESI) m/z 521.1 [M&#x02009;+&#x02009;H]<sup>+</sup>; HRMS calcd for C<sub>27</sub>H<sub>25</sub>ClN<sub>4</sub>O<sub>3</sub>S [M&#x02009;+&#x02009;H]<sup>+</sup> 521.1414, found 521.1441 (as free base)</p></sec></sec><sec id="S0002-S2003" disp-level="2"><title>DGAT-1 inhibition assay (IC<sub>50</sub>)</title><p>The activity of DGAT-1 inhibitors <italic>in&#x000a0;vitro</italic> was evaluated by using a human recombinant DGAT1 enzyme expressed in insect cells (SF9 cells). SF9 cells were homogenised by washing them with DPBS (Dulbecco&#x02019;s phosphate-buffered saline) and then suspending cell pellets with a tris buffer (250&#x02009;mM sucrose; 10&#x02009;mM Tris-HCl [pH 7.4]; proteinase inhibitor). The resulting mixture was centrifugally separated at 10,000 &#x000d7; <italic>g</italic> for 30&#x02009;min to remove the cell debris remaining in the lower layer thereof, and was centrifugally separated at 100,000 &#x000d7; <italic>g</italic> for 60&#x02009;min to obtain a microsomal membrane. Further, membrane fractions were resuspended by the tris buffer, and then stored at -80&#x02009;&#x000b0;C.</p><p>The activity of DGAT1 was measured according to the reported method<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. Specifically, 0.0001 &#x02013; 10 &#x003bc;&#x0039c; (final concentration, FC) of the test compounds were cultured at room temperature (25&#x02009;&#x000b0;C) for 15&#x02009;min with a 10 &#x003bc;&#x0039c; of SF9 microsomal protein solution and 100&#x02009;mM of MgCl<sub>2</sub> solution, and were then further cultured at room temperature (25&#x02009;&#x000b0;C) for 30&#x02009;min after the addition of 100 &#x003bc;&#x0039c; (FC in 12.5% EtOH) of 1,2-dioleyl-sn-glycerol and 30 &#x003bc;&#x0039c; (final conc.) of <xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>C-oleyl coenzyme A. The reaction was completed by the addition of 300&#x02009;&#x003bc;L of a mixed solution of 2-propanol/heptane (7:1), and radioactive triglyceride was separated from an organic solvent layer by using 200&#x02009;&#x003bc;L of heptane and 200&#x02009;&#x003bc;L of a 0.1&#x02009;M carbonate buffer (pH 9.5). The amount of triglyceride was measured by liquid scintillography (Perkin Elmer, USA) after mixing with an organic solvent and an equivalent amount of scintillation solvent (MicroScint-O, Perkin Elmer, USA). The effects of inhibiting DGAT1 were calculated as percent in comparison with a control material.</p></sec><sec id="S0002-S2004" disp-level="2"><title>Oral lipid tolerance test (OLTT)</title><sec id="S0002-S2004-S3001" disp-level="3"><title>Mouse</title><p>Male, Institute of Cancer Research (ICR) mice were obtained from OrientBio Inc. (Republic of Korea). ICR mice (8-weeks old, <italic>n</italic>&#x02009;=&#x02009;5/group) fasted 16&#x02009;h, received 5&#x02009;mL/kg corn oil via oral administration (p.o.) 30&#x02009;min after compound administration. Plasma was collected at different time points (0, 1, 2, and 4&#x02009;h).</p></sec><sec id="S0002-S2004-S3002" disp-level="3"><title>Dog</title><p>Beagle dogs (9&#x02009;months old, <italic>n</italic>&#x02009;=&#x02009;2/group) were obtained from Woojung Bio Inc. (Republic of Korea) were fasted for 16&#x02009;h and received heavy cream (2.7&#x02009;mL/kg), glucose (1&#x02009;g/kg), water (5.3&#x02009;mL/kg), and acetaminophen (20&#x02009;mg/kg p.o.) 1&#x02009;h after compound administration. Blood samples were collected at &#x02013;0.5, 0, 1, 2, and 4&#x02009;h.</p></sec></sec><sec id="S0002-S2005" disp-level="2"><title>Statistical analysis</title><p>Statistical analysis was performed using one-way ANOVA, followed by Dunnett&#x02019;s multiple comparison test using Prism 6.0 (GraphPad, USA). The Kruskal-Wallis test was applied when data did not pass the normality test.</p></sec></sec><sec sec-type="results" id="S0003" disp-level="1"><title>Results and discussion</title><p>We found that thieno[3,2-<italic>d</italic>]pyrimidine could be a core scaffold connecting an aryl moiety at one end to a cyclo-aliphatic carboxylic acid group at the other. Synthetic schemes for a series of thieno[3,2-<italic>d</italic>]pyrimidine derivatives are outlined in <xref ref-type="scheme" rid="SCH0001 SCH0002">Schemes 1 and 2</xref>.</p><p>Desired compounds <bold>14a</bold>&#x02013;<bold>14l</bold> were synthesised from commercially available 7-bromo-4-chlorothieno[3,2-<italic>d</italic>]pyrimidine (<bold>6)</bold>, as shown in <xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>. Consecutive Suzuki coupling reactions gave <bold>8</bold> and <bold>10.</bold> Compound <bold>9</bold> was prepared using the reported method<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>. Hydrogenation of <bold>10</bold>, followed by de-protection of the Boc group with trifluoroacetic acid afforded the key intermediate <bold>12</bold>. The aniline <bold>12</bold> was converted to amides <bold>14a</bold>&#x02013;<bold>14h</bold> or ureas <bold>14i</bold>&#x02013;<bold>14l</bold> by coupling with acid chlorides or aryl isocyanates, respectively, followed by hydrolysis with sodium hydroxide or lithium hydroxide.</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of thienopyrimidine derivatives. Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, 2&#x02009;N Na<sub>2</sub>CO<sub>3</sub>, 1,4-Dioxane; (b) H<sub>2</sub>, 20% PdOH, EtOH/1,4-Dioxane; (c) TFA, DCM, rt; (d) aryl chloride, pyridine, DCM 0&#x02009;&#x000b0;C to rt or aryl isocyanate, THF, 12&#x02009;h, rt; (e) NaOH or LiOH, THF/MeOH/H<sub>2</sub>O (1:1:1), rt.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1693555_SCH0001_B"/></fig><p>The activities of synthesised compounds were evaluated using SF9 insect cells expressing human DGAT-1<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>. The IC<sub>50</sub> values are summarised in <xref rid="t0001" ref-type="table">Table 1</xref>. A potent DGAT-1 inhibitor, <bold>LCQ-908</bold> (<bold>2</bold> or pradigastat) was used as a positive control. To optimise the alkyl chain length of the acid moiety, compound <bold>14b</bold> (<italic>n</italic>&#x02009;=&#x02009;1) was more potent than short chain <bold>14a</bold> (<italic>n</italic>&#x02009;=&#x02009;0) and long chain <bold>14c</bold> (<italic>n</italic>&#x02009;=&#x02009;2). The calculated lowest energy conformation model of <bold>14c</bold> provided that the distance between the terminal carboxylic acid and NH of urea was over 16&#x02009;&#x000c5;, which may result in reduced activity. <bold>14a</bold> exhibited a loss of activity, which suggested that the terminal carboxylic acid should be placed one-carbon away from cyclohexane. Next, structure-activity relationships for the aryl moiety on the left side were investigated, with derivatives bearing chain lengths the same as that of <bold>14b</bold>. 5-chloro-2-nitro phenyl (<bold>14d)</bold>, 2-trifluoromethylpyridinyl (<bold>14f)</bold>, 4-chloropyridinyl (<bold>14k)</bold>, and 5-bromopyridinyl (<bold>14l)</bold> derivatives had no activity (IC<sub>50</sub> &#x0003e;1&#x02009;&#x003bc;M), while <bold>14b</bold>, <bold>14c</bold>, <bold>14e</bold>, <bold>14h</bold>, and <bold>14j</bold> had good activity (IC<sub>50</sub> values of 0.3&#x02009;&#x003bc;M&#x02013;0.4&#x02009;&#x003bc;M). Compounds <bold>14g</bold> and <bold>14i</bold> were equipotent to the known compound <bold>2</bold>. The most potent compound, <bold>14i</bold>, was subjected to further investigation. <italic>Cis</italic> and <italic>trans</italic> isomers of <bold>14i</bold> were separated to determine the activity and properties of each isomer. As shown in <xref ref-type="scheme" rid="SCH0002">Scheme 2</xref>, the racemic mixture <bold>13</bold> was conveniently separated into <italic>cis</italic>-isomer <bold>15a</bold> and <italic>trans</italic>-isomers <bold>15b</bold> by the treatment with ethyl acetate. <bold>15a</bold> and <bold>15b</bold> exhibited greatly different solubility for ethyl acetate, and were soluble and insoluble for ethyl acetate, respectively. Hydrolysis of <bold>15a</bold> and <bold>15b</bold> afforded <italic>cis</italic> isomer <bold>17a</bold> and <italic>trans</italic> isomer <bold>17b,</bold> respectively.</p><fig id="SCH0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Reagents and conditions: (a) THF, rt; (b) separation by using ethyl acetate at 60&#x02013;70&#x02009;&#x000b0;C; filtrate for <bold>15a</bold> and solid for <bold>15b</bold>; (c) NaOH, THF/MeOH/H<sub>2</sub>O; (d) 1&#x02009;M NaOH, MeOH, rt.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1693555_SCH0002_B"/></fig><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>DGAT-1 inhibitors and their <italic>in&#x000a0;vitro</italic> data.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><col width="1*"/><tbody valign="top"><tr><td align="left"><inline-graphic xlink:href="IENZ_A_1693555_ILG0001_B.gif" content-type="black-white"/></td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label><sup>a</sup></label><p>Data present mean values.</p></fn></table-wrap-foot></table-wrap><p>Interestingly, the isomers <bold>17a</bold> and <bold>17b</bold> were more potent than mixture <bold>14i</bold>, and even compound <bold>2</bold>, in SF9 cells (<xref rid="t0002" ref-type="table">Table 2</xref>). However, pharmacokinetic studies demonstrated that <italic>cis</italic>-isomer <bold>17a</bold> had a much better profile than <italic>trans</italic>-isomer <bold>17b</bold> (<xref rid="t0003" ref-type="table">Table 3</xref>). <bold>17a</bold> had a shorter half-life (1.2&#x02009;h), but had much better bioavailability, compared to <bold>17b</bold>. In enzymatic assays, <bold>17a</bold> had an IC<sub>50</sub> of 61&#x02009;nM for DGAT-1 and displayed high off-target selectivity against DGAT-2, acyl-coenzyme A (CoA):cholesterol acyltransferases (ACAT1 and ACAT2) (<xref rid="t0002" ref-type="table">Table 2</xref>). ACATs have sequence homology to DGAT-1 and play essential roles in cholesterol homeostasis<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>. <bold>17b</bold> was not explored in the enzymatic assays due to its poor pharmacokinetic profile.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Enzyme and cellular inhibitory potencies for selected compounds.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="6" align="center">IC<sub>50</sub> (nM)<hr/></th></tr><tr><th align="left"><break/>Compound</th><th align="center">DGAT1(SF9)</th><th align="center">hDGAT1</th><th align="center">hDGAT2</th><th align="center">hACAT1</th><th align="center">hACAT2</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>2</bold></td><td align="char" char=".">157</td><td align="char" char=".">57</td><td align="char" char=".">&#x0003e;10,000</td><td align="char" char=".">&#x0003e;10,000</td><td align="char" char=".">&#x0003e;10,000</td></tr><tr><td align="left"><bold>17a</bold></td><td align="char" char=".">74</td><td align="char" char=".">61</td><td align="char" char=".">&#x0003e;10,000</td><td align="char" char=".">&#x0003e;10,000</td><td align="char" char=".">&#x0003e;10,000</td></tr><tr><td align="left"><bold>17b</bold></td><td align="char" char=".">89</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr></tbody></table></table-wrap><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Pharmacokinetic profiles of compounds <bold>17a, 17b</bold> in ICR mice.<xref ref-type="table-fn" rid="TF2"><sup>a</sup></xref></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Compounds</th><th align="center">17a</th><th align="center">17b</th></tr></thead><tbody valign="top"><tr><td align="left">AUC <sub>0&#x0223c;24</sub> (ng&#x000b7;h/mL)</td><td align="char" char=".">861.2</td><td align="char" char=".">233.7</td></tr><tr><td align="left"><italic toggle="yes">C</italic><sub>max</sub> (ng/mL)</td><td align="char" char=".">479.3</td><td align="char" char=".">74.8</td></tr><tr><td align="left">T<sub>1/2</sub> (h)</td><td align="char" char=".">1.2</td><td align="char" char=".">5.2</td></tr><tr><td align="left">Bioavailability (%)</td><td align="char" char=".">19</td><td align="char" char=".">0.7</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><label><sup>a</sup></label><p>All parameters were determined after oral administration (10&#x02009;mg/kg, <italic>n</italic>&#x02009;=&#x02009;3) and intravenous (iv) injection (3&#x02009;mg/kg, <italic>n</italic>&#x02009;=&#x02009;2) in ICR mice; both compounds were dissolved in a vehicle solution of DMSO/Tween80/saline (1:6:23) for iv., and 0.5% methylcellulose/0.5% Tween80 in distilled water for oral administration. Data represent mean values.</p></fn></table-wrap-foot></table-wrap><p>Considering potency, selectivity, and pharmacokinetic profiles, <bold>17a</bold> was investigated for further pharmacokinetic properties in four species, and results are summarised in <xref rid="t0004" ref-type="table">Tables 4</xref> and <xref rid="t0005" ref-type="table">5</xref>. <bold>17a</bold> exhibited low to moderate clearance and acceptable oral bioavailability in rat and dog.</p><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Oral pharmacokinetic profile of <bold>17a</bold> in rat and dog.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Parameters</th><th align="center">AUC 0&#x02009;&#x0223c;&#x02009;24 (ng&#x000b7;h/mL)</th><th align="center"><italic toggle="yes">T</italic> 1/2 (h)</th><th align="center">Cl (L/hr/kg))</th><th align="center">Bioavailability (%)</th></tr></thead><tbody valign="top"><tr><td align="left">Rat<xref ref-type="table-fn" rid="TF3"><sup>a</sup></xref></td><td align="char" char=".">18,594.5&#x02009;&#x000b1;&#x02009;6764.2</td><td align="char" char=".">3.0&#x02009;&#x000b1;&#x02009;0.4</td><td align="char" char=".">0.5&#x02009;&#x000b1;&#x02009;0.2</td><td align="char" char=".">30</td></tr><tr><td align="left">Dog<xref ref-type="table-fn" rid="TF4"><sup>b</sup></xref></td><td align="char" char=".">8243.0&#x02009;&#x000b1;&#x02009;2296.3</td><td align="char" char=".">3.6&#x02009;&#x000b1;&#x02009;0.7</td><td align="char" char=".">0.4&#x02009;&#x000b1;&#x02009;0.1</td><td align="char" char=".">53</td></tr></tbody></table><table-wrap-foot><fn id="TF3"><label><sup>a</sup></label><p>Dose; 3&#x02009;mg/kg for iv, 10&#x02009;mg/kg for po.; Vehicle: DMSO/Tween80/saline (1:6:23) for iv.; 0.5% methylcellulose/0.5% Twee80 in distilled water for po.</p></fn><fn id="TF4"><label><sup>b</sup></label><p>Dose: 1&#x02009;mg/kg for iv, 3&#x02009;mg/kg for po.; Vehicle: DMSO/Tween80/saline (1:3:26) for iv; 0.5% methylcellulose/0.5% Tween80 in distilled water for po.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0005" orientation="portrait" position="float"><label>Table 5.</label><caption><p><italic>In vitro</italic> microsomal stability and cytochrome P450 (CYP) inhibition assay of compound <bold>17a.</bold></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th colspan="4" align="center">Microsomal stability, (%)<xref ref-type="table-fn" rid="TF5"><sup>a</sup></xref><hr/></th><th colspan="5" align="center">CYPs enzyme inhibition, IC<sub>50</sub> (&#x003bc;M)<xref ref-type="table-fn" rid="TF6"><sup>b</sup></xref><hr/></th></tr><tr><th align="left">No</th><th align="center">Human</th><th align="center">Dog</th><th align="center">Rat</th><th align="center">Mouse</th><th align="center">CYP3A4</th><th align="center">CYP1A2</th><th align="center">CYP2C9</th><th align="center">CYP2C19</th><th align="center">CYP2D6</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>17a</bold></td><td align="char" char=".">94</td><td align="char" char=".">82</td><td align="char" char=".">87</td><td align="char" char=".">82</td><td align="char" char=".">16.2</td><td align="char" char=".">10.6</td><td align="char" char=".">2.9</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">8.7</td></tr></tbody></table><table-wrap-foot><fn id="TF5"><label><sup>a</sup></label><p>Remaining percent of metabolism by incubation of the parent molecule (5&#x02009;&#x003bc;M) with liver microsomes of mouse, rat, dog, and human for 60&#x02009;min (duplicate).</p></fn><fn id="TF6"><label><sup>b</sup></label><p>Data were analysed by a fluorescence detection method.</p></fn></table-wrap-foot></table-wrap><p><bold>17a</bold> exhibited durable metabolic stabilities, as shown in <xref rid="t0005" ref-type="table">Table 5</xref>. In particular, <bold>17a</bold> was metabolically stable in four species: human, dog, rat, and mouse. Further evaluation of <bold>17a</bold> was carried out for inhibition of clinically relevant cytochrome 450 (CYP) isoforms (3A4, 1A2, 2C9, 2C19, 2D6). No significant inhibition by <bold>17a</bold> was observed (<xref rid="t0005" ref-type="table">Table 5</xref>). Thus, <bold>17a</bold> would be very unlikely to affect the pharmacokinetics of other drugs.</p><p>To determine <italic>in&#x000a0;vivo</italic> efficacy, we evaluated the activity of <bold>17a</bold> against serum TAG level induced by the oral administration of corn oil (oral lipid tolerance test, OLTT; <xref ref-type="fig" rid="F0003">Figures 3</xref> and <xref ref-type="fig" rid="F0004">4</xref>), since intestinal targeted DGAT-1 inhibition results in a reduced serum TAG level<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. <bold>17a</bold> was orally administered to ICR mice at 3&#x02009;mg/kg or to dogs at 1&#x02009;mg/kg before administration of corn oil. As shown in <xref ref-type="fig" rid="F0003">Figure 3</xref>, <bold>17a</bold> showed significant activity, as potent as compound <bold>2,</bold> in reducing plasma TAG level.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Effect of <bold>17a</bold> in the oral lipid tolerance test (<italic>n</italic>&#x02009;=&#x02009;5, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001). Serum TG (or TAG) concentration was measured before and 1, 2, and 4&#x02009;h after oral administration of corn oil in ICR mice treated with <bold>17a</bold> (3&#x02009;mg/kg) or <bold>2</bold> (1&#x02009;mg/kg). Vehicle for <bold>2</bold>: 0.5% methylcellulose/0.5% Tween80 in distilled water, vehicle for <bold>17a</bold>: 0.5% Tween80 in distilled water.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1693555_F0003_C"/></fig><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Effect of <bold>17a</bold> in a canine oral lipid tolerance test (<italic>n</italic>&#x02009;=&#x02009;2, *<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001). The dog was treated with <bold>17a</bold> (po. 1&#x02009;mg/kg) or <bold>2</bold> (po. 1&#x02009;mg/kg) before oral administration of corn oil. Vehicle for <bold>2</bold>: 0.5% methylcellulose/0.5% Tween80 in distilled water, vehicle for <bold>17a</bold>: 0.5% Tween80 in distilled water.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1693555_F0004_C"/></fig><p>In addition, tissue distribution of <bold>17a</bold> was investigated. <bold>17a</bold> was orally administered to mice at 30&#x02009;mg/kg, and <bold>2</bold> was administrated as a positive control (<xref ref-type="fig" rid="F0005">Figure 5</xref>). The concentration levels of <bold>17a</bold> in the liver and small intestine were much higher than in other tissues, indicating that liver and small intestine are the main target organs of <bold>17a</bold>, while <bold>2</bold> showed much high concentrations in the liver and large intestine. Analysis of tissue-to-plasma ratios indicated that <bold>17a</bold> had favourable distributions in the liver and small intestine. Significant activity of <bold>17a</bold> in the OLTT appeared to result from high concentration in the small intestine, even though bioavailability of <bold>17a</bold> was not great in mice. This result could be proof of a pharmacokinetic&#x02013;pharmacodynamic correlation.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Tissue distribution of <bold>17a</bold> in mice. <bold>17a</bold> and <bold>2</bold> were orally administered to ICR mice at 30&#x02009;mg/kg (<italic>n</italic>&#x02009;=&#x02009;3). (a) AUC values of <bold>17a</bold> and <bold>2</bold> in indicated tissues. Each bar shows AUC obtained from concentrations measured at 0.5&#x02009;h, 1&#x02009;h, 2&#x02009;h, 4&#x02009;h, and 24&#x02009;h after dosing. Data represent mean value. (b) Tissue-to-plasma (T/P) ratio of <bold>17a</bold> and <bold>2</bold>. S.I.: small intestine, L.I.: large intestine.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1693555_F0005_C"/></fig></sec><sec sec-type="conclusions" id="S0004" disp-level="1"><title>Conclusion</title><p>We found that a novel series of thieno[3,2-<italic>d</italic>]pyrimidine derivatives had potent DGAT-1 inhibitory activity. A representative compound, <italic>cis</italic>-isomer <bold>17a</bold> showed potent DGAT-1 inhibitory activity, metabolic stability in four species, an acceptable pharmacokinetic profile in rodents and dogs, and a significant reduction of TAG in the OLTT in mice and dogs. In a tissue-distribution study, <bold>17a</bold> was mainly distributed to the liver and small intestine. Therefore, <bold>17a</bold> could be a candidate with considerable potential and deserves for further investigation.</p></sec></body><back><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kusminski</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Bickel</surname>
<given-names>PE</given-names></string-name>, <string-name><surname>Scherer</surname>
<given-names>PE.</given-names></string-name></person-group>
<article-title>Targeting adipose tissue in the treatment of obesity-associated diabetes</article-title>. <source>Nat Rev Drug Discov</source>
<year>2016</year>;<volume>15</volume>:<fpage>639</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">27256476</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subauste</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Burant</surname>
<given-names>CF.</given-names></string-name></person-group>
<article-title>Dgat: novel therapeutic target for obesity and type 2 diabetes mellitus</article-title>. <source>Curr Drug Targets Immune Endocr Metabol Disord</source>
<year>2003</year>;<volume>3</volume>:<fpage>263</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">14683457</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Capeau</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Insulin resistance and steatosis in humans</article-title>. <source>Diabetes Metab</source>
<year>2008</year>;<volume>34</volume>:<fpage>649</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">19195626</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kennedy</surname>
<given-names>EP.</given-names></string-name></person-group>
<article-title>Metabolism of lipides</article-title>. <source>Annu Rev Biochem</source>
<year>1957</year>;<volume>26</volume>:<fpage>119</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">13488391</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yen</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Stone</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Koliwad</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Thematic review series: glycerolipids. Dgat enzymes and triacylglycerol biosynthesis</article-title>. <source>J Lipid Res</source>
<year>2008</year>;<volume>49</volume>:<fpage>2283</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">18757836</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bhatt-Wessel</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Jordan</surname>
<given-names>TW</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>L.</given-names></string-name></person-group>
<article-title>Role of dgat enzymes in triacylglycerol metabolism</article-title>. <source>Arch Biochem Biophys</source>
<year>2018</year>;<volume>655</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">30077544</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Cases</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jensen</surname>
<given-names>DR</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking dgat</article-title>. <source>Nat Genet</source>
<year>2000</year>;<volume>25</volume>:<fpage>87</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">10802663</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stone</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Myers</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Watkins</surname>
<given-names>SM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Lipopenia and skin barrier abnormalities in dgat2-deficient mice</article-title>. <source>J Biol Chem</source>
<year>2004</year>;<volume>279</volume>:<fpage>11767</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">14668353</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Birch</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Buckett</surname>
<given-names>LK</given-names></string-name>, <string-name><surname>Turnbull</surname>
<given-names>AV.</given-names></string-name></person-group>
<article-title>Dgat1 inhibitors as anti-obesity and anti-diabetic agents</article-title>. <source>Curr Opin Drug Discov Devel</source>
<year>2010</year>;<volume>13</volume>:<fpage>489</fpage>&#x02013;<lpage>96</lpage>.</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>King</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Judd</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Souers</surname>
<given-names>AJ.</given-names></string-name></person-group>
<article-title>Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents</article-title>. <source>Expert Opin Ther Pat</source>
<year>2010</year>;<volume>20</volume>:<fpage>19</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">20021283</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Motiwala</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kandre</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Birar</surname>
<given-names>V</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exploration of pyridine containing heteroaryl analogs of biaryl ureas as dgat1 inhibitors</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2011</year>;<volume>21</volume>:<fpage>5812</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21868220</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McCoull</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Addie</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Birch</surname>
<given-names>AM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification, optimisation and in&#x000a0;vivo evaluation of oxadiazole dgat-1 inhibitors for the treatment of obesity and diabetes</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2012</year>;<volume>22</volume>:<fpage>3873</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22608962</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meyers</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gaudet</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Tremblay</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The dgat1 inhibitor lcq908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome</article-title>. <source>J Clin Lipidol</source>
<year>2012</year>;<volume>6</volume>:<fpage>266</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>King</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Segreti</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Larson</surname>
<given-names>KJ</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the zucker fatty rat and the hyperlipidemic hamster</article-title>. <source>J Pharmacol Exp Ther</source>
<year>2009</year>;<volume>330</volume>:<fpage>526</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">19478132</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Souers</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Voorbach</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Validation of diacyl glycerolacyltransferase i as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor</article-title>. <source>J Med Chem</source>
<year>2008</year>;<volume>51</volume>:<fpage>380</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">18183944</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qian</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wertheimer</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Ahmad</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes</article-title>. <source>J Med Chem</source>
<year>2011</year>;<volume>54</volume>:<fpage>2433</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">21413799</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harrison</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Bauer</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Berdichevsky</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Successful strategies for mitigation of a preclinical signal for phototoxicity in a dgat1 inhibitor</article-title>. <source>ACS Med Chem Lett</source>
<year>2019</year>;<volume>10</volume>:<fpage>1128</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">31413796</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>Z-C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Accelerating the discovery of dgat1 inhibitors through the application of parallel medicinal chemistry (pmc)</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2019</year>;<volume>29</volume>:<fpage>1380</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">30952592</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nakajima</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Chatelain</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Clairmont</surname>
<given-names>KB</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of an orally bioavailable benzimidazole diacylglycerol acyltransferase 1 (dgat1) inhibitor that suppresses body weight gain in diet-induced obese dogs and postprandial triglycerides in humans</article-title>. <source>J Med Chem</source>
<year>2017</year>;<volume>60</volume>:<fpage>4657</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">28498655</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Devani</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Shishoo</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Pathak</surname>
<given-names>US</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of 3-substituted thieno [2, 3-d] pyrimidin-4(3h)-one-2-mercaptoacetic acids and their ethyl esters for pharmacological screening</article-title>. <source>J Pharm Sci</source>
<year>1976</year>;<volume>65</volume>:<fpage>660</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">932932</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Dow</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Munchhof</surname>
<given-names>MJ</given-names></string-name></person-group>, <chapter-title>Preparation of substituted dihydropyrimidooxazepine derivatives for use as antiobesity agents</chapter-title>. In: <source>Preparation of substituted dihydropyrimidooxazepine derivatives for use as antiobesity agents; 20080722</source>; <publisher-loc>WO</publisher-loc>: <publisher-name>Pfizer Products Inc</publisher-name>.; <year>2009</year>.</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Birch</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Birtles</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Buckett</surname>
<given-names>LK</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor</article-title>. <source>J Med Chem</source>
<year>2009</year>;<volume>52</volume>:<fpage>1558</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">19256504</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pramfalk</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Eriksson</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Parini</surname>
<given-names>P.</given-names></string-name></person-group>
<article-title>Cholesteryl esters and acat</article-title>. <source>Eur J Lipid Sci Technol</source>
<year>2012</year>;<volume>114</volume>:<fpage>624</fpage>&#x02013;<lpage>33</lpage>.</mixed-citation></ref></ref-list></back></article>